首页|实炎方对湿热蕴肠型溃疡性结肠炎患者的临床疗效

实炎方对湿热蕴肠型溃疡性结肠炎患者的临床疗效

扫码查看
目的 探讨实炎方对湿热蕴肠型溃疡性结肠炎患者的临床疗效.方法 82 例患者随机分为对照组和观察组,每组 41 例,对照组给予美沙拉嗪肠溶片,观察组在对照组基础上加用实炎方,疗程 8 周.检测临床疗效、中医证候评分、炎症因子(白细胞介素-6、白细胞介素-22、白细胞介素-33)、肠黏膜屏障功能指标(二胺氧化酶、D-乳酸、内毒素)、肠道菌群(大肠杆菌、肠球菌、双歧杆菌、乳酸杆菌)、GQOLI-74 评分变化.结果 观察组总有效率高于对照组(P<0.05).治疗后,2 组中医证候评分、血清炎症因子、肠黏膜屏障功能指标降低(P<0.05),GQOLI-74 升高(P<0.05),肠球菌减少(P<0.05),双歧杆菌、乳酸杆菌增加(P<0.05),以观察组更明显(P<0.05).结论 实炎方可提高溃疡性结肠炎患者生活质量,临床疗效明显.
Clinical effects of Shiyan Prescription on patients with ulcerative colitis due to Bowel Dampness-Heat Stagnation
AIM To explore the clinical effects of Shiyan Prescription on patients with ulcerative colitis due to Bowel Dampness-Heat Stagnation.METHODS Eighty-two patients were randomly assigned into control group(41 cases)for 8-week administration of Mesalazin Enteric-coated Tablets,and observation group(41 cases)for 8-week administration of both Shiyan Prescription and Enteric-coated Tablets.The changes in clinical effects,TCM syndrome scores,serum inflammatory factors(interleukin-6,interleukin-22,interleukin-33),intestinal mucosal barrier function indices(diamine oxidase,D-lactic acid,endotoxin),intestinal flora(Escherichia coli,Enterococcus,Bifidobacterium,Lactobacillus)and GQOLI-74 scores were detected.RESULTS The observation group demonstrated higher total effective rate than the control group(P<0.05).After the treatment,the two groups displayed decreased TCM syndrome scores,serum inflammatory factors,intestinal mucosal barrier function indices(P<0.05),increased GQOLI-74 scores(P<0.05),reduced Enterococcus(P<0.05),and enhanced Bifidobacterium,Lactobacillus(P<0.05),especially for the observation group(P<0.05).CONCLUSION For the patients with ulcerative colitis due to Bowel Dampness-Heat Stagnation,Shiyan Prescription can enhance life quality with obvious clinical effects.

Shiyan PrescriptionMesalazin Enteric-coated Tabletsulcerative colitisBowel Dampness-Heat Stagnation

黄李、杨巍、彭云花、陈天、裴艳妮、陆宏

展开 >

上海中医药大学研究生院,上海 201203

上海中医药大学附属曙光医院肛肠科,上海 201203

实炎方 美沙拉嗪肠溶片 溃疡性结肠炎 湿热蕴肠

上海市临床重点专科 2019年评审项目上海市卫生健康委员会科研课题上海中医药大学附属曙光医院"四明临床研究专项"

shslczdzk0430220204Y0180SGKJLL-202006

2024

中成药
国家食品药品监督管理局,信息中心中成药信息站,上海中药行业协会

中成药

CSTPCD北大核心
影响因子:1.217
ISSN:1001-1528
年,卷(期):2024.46(8)
  • 11